- Paper Report
- Open Access
Noninvasive ventilation for the immunosuppressed patient?
- Richard Venn1
© Biomed Central Ltd 2001
- Received: 28 March 2001
- Published: 4 December 2001
- Haematological malignancy
- noninvasive ventilation
- respiratory failure
Intubation and mechanical ventilation for respiratory failure in the immunosuppressed patient has a mortality rate ranging from 60 to 100%. Aggressive measures to avoid intubation may, therefore, improve outcome in these patients and avoid invasive therapy, which is often futile. Noninvasive ventilation (NIV) at an early stage in the respiratory failure of these patients may achieve this goal. This trial compares the efficacy of NIV with standard medical therapy.
Requirement for intubation, complications, and ICU and hospital mortality were significantly better in those patients receiving early NIV. Hospital mortality was 50% and 81% (P = 0.02) for the NIV and conventional groups, respectively. Patients who required intubation and mechanical ventilation in either group, had a 100% mortality. In the immunocompromised, initiation of NIV early in the course of hypoxic respiratory failure prevents intubation, reduces complications, and thereby improves survival.
Prospective randomised controlled trial of noninvasive ventilation versus conventional medical treatment in immunosuppressed patients (26 in each group) with early hypoxaemic respiratory failure.
Hill NS: Noninvasive ventilation for immunocompromised patients. New Engl J Med 2001, 344:522-523.